Loading…
Beyond Air, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in XAIR.
▼ -99.9% over 5Y.
today you would have $0.64▼ -99.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 9 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $2.85 | $14.52 | $143.60 | $784.00 | $2,596.00 | $3,776.00 | $2,108.00 | $2,092.00 | $1,860.00 | |
| P/S | 10.7x | 0.3x | 0.9x | 14.2x | — | — | 236.8x | 63.8x | 7.2x | — |
| P/B | 2.7x | 0.3x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SILOSilo Pharma, Inc. | $2.54 | — | 0.5x | — | -91.23% | $4.45M |
| SBFMSunshine Biopharma Inc. | $1.15 | — | 0.0x | — | -21.92% | $4.46M |
| ELABPMGC Holdings Inc. | $5.31 | — | 0.2x | — | -105.22% | $4.3M |
| VVOSVivos Therapeutics, Inc. | $0.22 |
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Company description provided by Yahoo Finance.
| 0.2x |
| 0.7x |
| 1.6x |
| 2.7x |
| 6.8x |
| 4.9x |
| 13.7x |
| 25.3x |
| EPS | -$80.20 | -$275.40 | -$728.00 | -$744.00 | -$672.00 | -$508.00 | -$712.00 | -$308.00 | -$672.00 |
| Profit margin | -1346.52% | -432.99% | -1258.43% | -5197.76% | — | — | -2620.27% | -1434.61% | -84.91% | — |
| ROE | -162.95% | -542.75% | -343.26% | -240.51% | -147.21% | -59.39% | -75.09% | -110.23% | -162.95% | -693.94% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| -8585.26% |
| $4.52M |
| APVOAptevo Therapeutics Inc. | $2.37 | 0.0x | 0.6x | — | -420.34% | $4.26M |
| XRTXXORTX Therapeutics Inc. | $2.34 | — | 1.6x | — | -99.24% | $4.25M |